EUVIMEDEUVIMED entdecken
Crossref

ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer

Tian Zeng, Qingxi Luo, Li Yang, Feifan Hou, Yongqi Zhao, Xueru Liu, Ni Jiang, Juan Zou, Yukun Li

Oncology Research · 2026 · 1-10

DOI: 10.32604/or.2026.084046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Tian Zeng und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Zeng, T., Luo, Q., Yang, L., Hou, F., Zhao, Y., Liu, X., Jiang, N., Zou, J., & Li, Y. (2026). ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.084046

Vancouver

Zeng T, Luo Q, Yang L, Hou F, Zhao Y, Liu X, et al. ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.084046

BibTeX
@article{Zeng2026,
  author = {Zeng, Tian and Luo, Qingxi and Yang, Li and Hou, Feifan and Zhao, Yongqi and Liu, Xueru and Jiang, Ni and Zou, Juan and Li, Yukun},
  title = {ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer},
  journal = {Oncology Research},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {1--10},
  doi = {10.32604/or.2026.084046}
}
Kostenlos starten →